Prognostic factors associated with 18FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment
Purpose This study aimed to determine the pathological complete response (pCR), overall survival (OS), and disease-free survival (DFS) in patients with locally advanced esophageal squamous cell carcinoma (ESCC) using post-neoadjuvant chemoradiotherapy (nCRT) F-18-fluorodeoxyglucose (18FDG). Methods This is a retrospective study of patients with locally advanced ESCC receiving nCRT and then esophagectomy between January 2011 and December 2018 in the Tri-Service General Hospital, Taipei, Taiwan. A total of 50 patients were enrolled in the study. Survival analysis was performed using the Kaplan–Meier method and Cox proportional hazards model. Univariate and multivariate analysis were used to determine the independent prognostic factors. Results Fifty patients were enrolled in the study, and 18 had pathological complete response. Post-nCRT SUVmax ≥ 3 is a poor prognostic factor associated with overall survival (HR: 3.665, P = 0.013) and disease-free survival (HR: 3.417, P = 0.011). Poor prognosis was found in the non-pCR plus post-nCRT SUVmax ≥ 3 group compared with pCR plus post-nCRT SUVmax < 3 group. Conclusions SUVmax ≥ 3 is a poor prognostic factor in esophageal squamous cell carcinoma after trimodality treatment, even in patients having pathological complete response..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
BMC cancer - 22(2022), 1 vom: 14. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feng, Wei-Hsiang [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Esophageal squamous cell carcinoma |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1186/s12885-022-09852-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR050852701 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR050852701 | ||
| 003 | DE-627 | ||
| 005 | 20230507232412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230507s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-022-09852-2 |2 doi | |
| 035 | |a (DE-627)SPR050852701 | ||
| 035 | |a (SPR)s12885-022-09852-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feng, Wei-Hsiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic factors associated with 18FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Purpose This study aimed to determine the pathological complete response (pCR), overall survival (OS), and disease-free survival (DFS) in patients with locally advanced esophageal squamous cell carcinoma (ESCC) using post-neoadjuvant chemoradiotherapy (nCRT) F-18-fluorodeoxyglucose (18FDG). Methods This is a retrospective study of patients with locally advanced ESCC receiving nCRT and then esophagectomy between January 2011 and December 2018 in the Tri-Service General Hospital, Taipei, Taiwan. A total of 50 patients were enrolled in the study. Survival analysis was performed using the Kaplan–Meier method and Cox proportional hazards model. Univariate and multivariate analysis were used to determine the independent prognostic factors. Results Fifty patients were enrolled in the study, and 18 had pathological complete response. Post-nCRT SUVmax ≥ 3 is a poor prognostic factor associated with overall survival (HR: 3.665, P = 0.013) and disease-free survival (HR: 3.417, P = 0.011). Poor prognosis was found in the non-pCR plus post-nCRT SUVmax ≥ 3 group compared with pCR plus post-nCRT SUVmax < 3 group. Conclusions SUVmax ≥ 3 is a poor prognostic factor in esophageal squamous cell carcinoma after trimodality treatment, even in patients having pathological complete response. | ||
| 650 | 4 | |a Esophageal squamous cell carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a FDG-PET/CT |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SUVmax |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pathological complete response |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prognostic factors |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chen, Ying-Yi |4 aut | |
| 700 | 1 | |a Kuo, Yen‐Shou |4 aut | |
| 700 | 1 | |a Lin, Kuan-Hsun |4 aut | |
| 700 | 1 | |a Tsai, Yuan-Ming |4 aut | |
| 700 | 1 | |a Wu, Ti-Hui |4 aut | |
| 700 | 1 | |a Huang, Hsu-Kai |4 aut | |
| 700 | 1 | |a Huang, Tsai-Wang |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 22(2022), 1 vom: 14. Juli |w (DE-627)SPR027602656 |w (DE-600)2041352-X |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g day:14 |g month:07 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12885-022-09852-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |b 14 |c 07 | ||